News|Podcasts|November 16, 2026

Pharmaceutical Executive Daily: FDA Approves Three New Therapies

FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, FDA approves three new therapies — Genentech’s Gazyva for kidney disease, Alexion’s Klygefa for myasthenia gravis, and Teva’s Igalmi for psychiatric agitation — a dealmaking roundup covers Johnson & Johnson’s $2.2 billion acquisition of Ollin Biosciences, Eli Lilly’s up to $1.5 billion deal for Calytrix Bio, AmyriAD Therapeutics’ acquisition of the AD04 Alzheimer’s program, and Sanofi’s collaboration with Seawolf Therapeutics, and Ron Lanton speaks with Kevin Caldwell of Ossium Health on rebuilding bone marrow transplants around deceased-donor marrow.

FDA has approved three new therapies this week, including Genentech’s Gazyva (obinutuzumab) as the first and only treatment for primary membranous nephropathy, showing a 36.1% complete proteinuria remission rate at 104 weeks versus 5.7% with tacrolimus in the Phase III MAJESTY trial. Separately, FDA approves Alexion’s Klygefa (gefurulimab), a once-weekly, self-administered C5 inhibitor for generalized myasthenia gravis, and Teva’s Igalmi (dexmedetomidine) sublingual film, the first at-home option for agitation in schizophrenia-spectrum and bipolar disorders.

A wave of dealmaking sweeps the industry this week, led by Johnson & Johnson’s agreement to acquire Ollin Biosciences for $2.2 billion upfront plus up to $1.125 billion in milestones, an ophthalmology deal partly funded by a $750 million commitment from Blackstone Life Sciences. Eli Lilly separately agrees to acquire Calytrix Bio for up to $1.5 billion to gain a biparatopic antibody for calreticulin-driven blood cancers, while AmyriAD Therapeutics acquires ADvantage Therapeutics’ AD04 Alzheimer’s program and Sanofi enters a collaboration with Seawolf Therapeutics worth up to $1.2 billion in bleeding disorder research.

Finally, Ron Lanton speaks with Kevin Caldwell, chief executive officer and co-founder of Ossium Health, on how the company is rebuilding bone marrow transplants around banked, deceased-donor marrow rather than living donors. Caldwell argues the approach can cut wait times from a standard of care of 12 to 15 weeks to as little as 31 hours, while preserving over 90% of cells after cryopreservation, as Ossium works to scale from roughly three donors processed per day toward more than 100 globally.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.